NCT05295940 is a Phase 1 clinical trial of LY3841136 in Obesity, sponsored by Eli Lilly and Company.

Who is sponsoring NCT05295940?

NCT05295940 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT05295940?

Interventions in NCT05295940: LY3841136, Placebo.

What condition does NCT05295940 study?

NCT05295940 studies Obesity, Healthy.

Is NCT05295940 still recruiting?

NCT05295940 is currently completed. Last updated 1 April 2024.

Last reviewed 2024-04-01 · How we verify

NCT05295940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY3841136 in Healthy and Overweight Participants

Completed Phase 1 Last updated 1 April 2024

What this trial tests

Phase 1 trial testing LY3841136 in Obesity in 148 participants. Completed in 25 January 2024.

Timeline

30 March 2022

Primary endpoint
25 January 2024

25 January 2024

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	148
Start date	30 March 2022
Primary completion	25 January 2024
Estimated completion	25 January 2024
Sites	3 locations across United States

Drugs / interventions tested

LY3841136 — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →
Healthy — all drugs for Healthy →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 65, any sex, with Obesity or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, et al · · 2023 · cited 260× · PMID 36992862 · DOI 10.1016/j.eclinm.2023.101882
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
Briere DA, Qu H, Lansu K, He MM, et al · · 2025 · cited 10× · PMID 41109426 · DOI 10.1016/j.molmet.2025.102271
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.
Sidrak WR, Kalra S, Kalhan A. · · 2024 · cited 8× · PMID 39676791 · DOI 10.4103/ijem.ijem_442_23
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, et al · · 2026 · cited 1× · PMID 41559929 · DOI 10.1111/dom.70439

Verify or expand the search:

Other trials of LY3841136

Trials testing the same drug.

NCT06297616 — A Study of LY3841136 in Japanese Participants With Obesity or Overweight · Phase 1 · completed
NCT06345066 — A Study of LY3841136 in Overweight and Obese Participants · Phase 1 · completed
NCT06230523 — A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight · Phase 2 · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05295940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 1 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05295940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing